TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6383166

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double-contrast barium meal
Number of subjects: 100
Study: 3676232

Group type: EXPERIMENTAL
Intervention: Low-energy diet with egg supplementation (two whole eggs and two egg yolks daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-energy diet with egg supplementation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dietary regimen of four eggs per day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-cholesterol intake
Number of subjects: 17
Study: 29861225

Group type: EXPERIMENTAL
Intervention: Unilateral thoracic PA in slump position (SLUMP group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Posterior‐to‐anterior (PA) rotatory thoracic passive accessory intervertebral mobilization (PAIVM) (PA group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo intervention (Placebo group)
Number of subjects: 60
Study: 28222825

Group type: EXPERIMENTAL
Intervention: Universal prevention (Climate Schools)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Selective prevention (Preventure)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Combined prevention (Climate Schools and Preventure; CAP)
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Health education as usual (control)
Number of subjects: 2190
Study: 26036465

Group type: EXPERIMENTAL
Intervention: Tailored brief intervention (BI)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Control
Number of subjects: 957
Study: 23930204

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) in combination with capecitabine (C) and mitomycin C (M)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 302
Study: 20199404

Group type: EXPERIMENTAL
Intervention: Benzyl alcohol lotion 5% (BAL 5%)
Number of subjects: 695
Study: 18312045

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 18240

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 18240
Study: 16557041

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (AA) + mood stabilizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study: 11966338

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 5499

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5499
Study: 9816888

Group type: EXPERIMENTAL
Intervention: ANCA-positive sera from systemic vasculitis patients (titre > or = 4:40)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: ANCA-negative GN sera
Number of subjects: 191

Group type: COMPARATOR
Intervention: Normal healthy individuals (negative control group)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Second negative reference system without serum
Number of subjects: 191
Study: 7663809

Group type: EXPERIMENTAL
Intervention: Sustained Maximal Inflations (SMI)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Single‐handed percussions (SSP)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 228
Study: 2526933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg x 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (1000 mg, 11 h prior to study)
Number of subjects: 9
Study: 71605

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 0
Study: 31747786

Group type: EXPERIMENTAL
Intervention: Incident NSAID use
Number of subjects: 17423

Group type: COMPARATOR
Intervention: NSAID use at baseline
Number of subjects: 17423
Study: 29948437

Group type: EXPERIMENTAL
Intervention: Olweus Bully Prevention Program (OBPP)
Number of subjects: 1791
Study: 27116023

Group type: EXPERIMENTAL
Intervention: Opioid dosing (morphine and oxycodone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pain intensity scores
Number of subjects: 44
Study: 24618401

Group type: EXPERIMENTAL
Intervention: Weekly application of dehydrated human amnion/chorion membrane allograft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biweekly application of dehydrated human amnion/chorion membrane allograft
Number of subjects: 40
Study: 22324425

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 18
Study: 21095282

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Highest uric acid quartile (>10.4 mg/dL)
Number of subjects: 1152
Study: 18479800

Group type: EXPERIMENTAL
Intervention: Fiber posts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite resin cores without fiber posts (Control)
Number of subjects: 0
Study: 16007279

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14705265

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy over five years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with permanent reduction in breast cancer incidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with further treatment effects preventing new breast cancers for up to 10 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with delayed breast cancer incidence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10638388

Group type: EXPERIMENTAL
Intervention: Standardised meal at 1.5 h after baseline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standardised meal at 5.5 h after baseline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 12
Study: 7856426

Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 9310

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9310
Study: 2203218

Group type: EXPERIMENTAL
Intervention: 0.5% timolol and 2% or 4% pilocarpine combination eye drops
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.5% timolol alone
Number of subjects: 33
Study: 7387807

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg kg‐1 followed by pancuronium 0.05 mg kg‐1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Suxamethonium before pancuronium
Number of subjects: 49
Study: 29981569

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid solution
Number of subjects: 528

Group type: COMPARATOR
Intervention: Intravenous dextrose solution
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 528

Group type: COMPARATOR
Intervention: Exclusive breastmilk
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Taste/smell given before gastric tube feeds
Number of subjects: 528

Group type: COMPARATOR
Intervention: Taste/smell not given before gastric tube feeds
Number of subjects: 528
Study: 26775091

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) infiltration at the rotator cuff defect
Number of subjects: 40

Group type: COMPARATOR
Intervention: No PRP (control group)
Number of subjects: 40
Study: 24653653

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors and lifestyle modification
Number of subjects: 234

Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 234
Study: 23158704

Group type: EXPERIMENTAL
Intervention: Home visits by clinical nurse specialists every fourth month for 2 years (n = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 102
Study: 19688297

Group type: EXPERIMENTAL
Intervention: Imatinib in combination with hydroxyurea (HU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea (HU) monotherapy
Number of subjects: 0
Study: 18625672

Group type: EXPERIMENTAL
Intervention: Restrictive pattern (RP) defined by reduced FVC and normal FEV1/FVC ratio
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Restrictive pattern (RP) defined by reduced FVC and FEV1/FVC ratio of > or = 85%
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe restrictive pattern (RP)
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: Obstructive pattern (OP)
Number of subjects: 2396

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) level > 3.0 mg/L
Number of subjects: 2396
Study: 15645268

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IVM) - 3 mg i.v. morphine after spinal anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) - 0.3 mg morphine with bupivacaine during spinal anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (IAM) - 3 mg intra-articular morphine diluted in 10 ml saline before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C) - no additional drugs
Number of subjects: 60
Study: 11788624

Group type: EXPERIMENTAL
Intervention: 2 mg mifepristone daily for 120 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 120 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 2 mg mifepristone daily for 120 days (Shanghai)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 120 days (Shanghai)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both doses of mifepristone
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 98
Study: 10744888

Group type: EXPERIMENTAL
Intervention: Yogurt sweetened with 3.75% sucrose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yogurt sweetened with 7.5% sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filter paper method
Number of subjects: 0
Study: 8692549

Group type: EXPERIMENTAL
Intervention: Combination of ondansetron and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study: 1678236

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone 17‐valerate cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% prednicarbate cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle of 0.25% prednicarbate cream
Number of subjects: 0
Study: 6124991

Group type: EXPERIMENTAL
Intervention: TEM 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TEM 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MPD + TEM 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MPD + TEM 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CAF + TEM 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CAF + TEM 30 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: CAF (150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: MPD (10 mg)
Number of subjects: 8
Study: 31269599

Group type: EXPERIMENTAL
Intervention: Group B (80 kV, 350 mgI/kg, ASIR-V from 10% to 100%)
Number of subjects: 80
Study: 29578192

Group type: EXPERIMENTAL
Intervention: RFA alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RFA combined with alcohol
Number of subjects: 50
Study: 27445325

Group type: EXPERIMENTAL
Intervention: 1:1 match
Number of subjects: 132

Group type: COMPARATOR
Intervention: No match
Number of subjects: 132
Study: 24517167

Group type: EXPERIMENTAL
Intervention: Family group conferencing (FG-c)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study: 22978729

Group type: EXPERIMENTAL
Intervention: Hotline consult
Number of subjects: 243

Group type: COMPARATOR
Intervention: No hotline consult
Number of subjects: 243
Study: 20078608

Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: telcagepant 800 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: telcagepant
Number of subjects: 12
Study: 17587399

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day (maximum 200 mg/day) of oral diazoxide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16258098

Group type: EXPERIMENTAL
Intervention: Antibiotics plus G-CSF (ciprofloxacin and roxithromycin with G-CSF on days 4 to 13)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Antibiotics alone (ciprofloxacin and roxithromycin)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Antibiotics plus G-CSF
Number of subjects: 175

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 175
Study: 12011969

Group type: EXPERIMENTAL
Intervention: HR 500 mg tid (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HR 1 g tid (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HR 1 g/day (Group D)
Number of subjects: 90
Study: 10438378

Group type: EXPERIMENTAL
Intervention: stavudine/didanosine/hydroxyurea
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: stavudine/didanosine
Number of subjects: 18
Study: 8292945

Group type: EXPERIMENTAL
Intervention: Conventional ties
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bow ties
Number of subjects: 15
Study: 3318623

Group type: EXPERIMENTAL
Intervention: Yellow mercuric oxide 1% bid (41 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (37 patients)
Number of subjects: 78
Study: 29861066

Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reciproc
Number of subjects: 0
Study: 27084825

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg, 110 mg twice daily for 4 days)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 24670356

Group type: EXPERIMENTAL
Intervention: GSTP1 genotypes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CC/CT+TT (wild type GSTP1 exon 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GSTP1 mutant genotype of exon 5 (GG), GSTP1 mutant and heterozygous genotypes of exon 6 (TT and CT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Null GSTM1, null GSTT1 and joint GSTM1/GSTT1 null genotypes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum GST
Number of subjects: 30
Study: 22517057

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 88
Study: 21626817

Group type: EXPERIMENTAL
Intervention: Phenotropil, 400 mg/day for 1 year
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no phenotropil)
Number of subjects: 400
Study: 16931161

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program (CRP) - 8 weeks, hospital-based supervised exercise training (3 times per week, average intensity of 65% VO(2peak)) and individual education sessions.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program (CRP) - 8 weeks, hospital-based supervised exercise training.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group - instructed on a home-based exercise regimen without contact during the 8 weeks.
Number of subjects: 60
Study: 16140624

Group type: EXPERIMENTAL
Intervention: Test substances (glue, body wash solution, dryer sheet)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Body wash solution
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dryer sheets
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control substances (unscented shampoo and clean air)
Number of subjects: 17
Study: 12125902

Group type: EXPERIMENTAL
Intervention: Structured psychoeducational intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ward
Number of subjects: 0
Study: 10340202

Group type: EXPERIMENTAL
Intervention: Individual pre-test counselling
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Group pre-test counselling
Number of subjects: 3958
Study: 8712125

Group type: EXPERIMENTAL
Intervention: Aminophylline (400 mg, oral administration for 90 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerin (0.3 mg, sublingual)
Number of subjects: 20
Study: 1763646

Group type: EXPERIMENTAL
Intervention: Betahistine dihydrochloride
Number of subjects: 55

Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 55
Study: 7077550

Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement plus positive expectancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement plus negative expectancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement of pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 31730554

Group type: EXPERIMENTAL
Intervention: Initial prescription of 30 hydrocodone/acetaminophen pills (5/325 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Initial prescription of 10 hydrocodone/acetaminophen pills (5/325 mg)
Number of subjects: 200
Study: 27101805

Group type: EXPERIMENTAL
Intervention: Tadalafil 20‐mg (on‐demand)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Sildenafil 100‐mg (on‐demand)
Number of subjects: 383
Study: 26226090

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) with routine primary care; 12 weekly 50-min sessions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine Primary Care
Number of subjects: 66
Study: 23947143

Group type: EXPERIMENTAL
Intervention: Chaihu Shugan San
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model control group
Number of subjects: 0
Study: 21475078

Group type: EXPERIMENTAL
Intervention: RENEW training (standard exercise and RENEW)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard exercise (STAND)
Number of subjects: 19
Study: 19300232

Group type: EXPERIMENTAL
Intervention: Ultrapro lightweight mesh in the sublay position
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no mesh)
Number of subjects: 54
Study: 17594732

Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilators
Number of subjects: 0
Study: 15083940

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neostigmine (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11475343

Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin-containing solution
Number of subjects: 21
Study: 9727896

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus metformin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9581674

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided liver biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind percutaneous liver biopsy
Number of subjects: 0
Study: 2153334

Group type: EXPERIMENTAL
Intervention: Acetate infusion (2.5 mmol/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acetate infusion (2.5 mmol/min) with glucose (20 g/m2 body surface area)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bicarbonate infusion (2.8 mmol/min)
Number of subjects: 15
Study: 273932

Group type: EXPERIMENTAL
Intervention: Mouthwash formulations (specific formulations not detailed)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Independent examinations of the six selected teeth
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Partial scores
Number of subjects: 66
Study: 31366875

Group type: EXPERIMENTAL
Intervention: β-CRX-rich orange juice (125 mL, after breakfast)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (β-CRX removed from orange juice, 125 mL, after breakfast)
Number of subjects: 23
Study: 28114921

Group type: EXPERIMENTAL
Intervention: Humidification group (high flow CO2 warming system with standard care)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (standard care alone)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Humidification group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 25765784

Group type: EXPERIMENTAL
Intervention: Four mini-implants (GI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Two mini-implants (GII)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Two standard implants (GIII)
Number of subjects: 120
Study: 23866802

Group type: EXPERIMENTAL
Intervention: External pleural suction (‐15 cmH2O, group A)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No external suction (control arm, group B)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: External pleural suction (‐15 cmH2O, group A) in anatomic resection subgroup
Number of subjects: 500

Group type: COMPARATOR
Intervention: No external suction (control arm, group B) in anatomic resection subgroup
Number of subjects: 500
Study: 21696308

Group type: EXPERIMENTAL
Intervention: T12PR48 group (telaprevir for 12 weeks and peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Lead-in T12PR48 group (4 weeks of peginterferon plus ribavirin followed by 12 weeks of telaprevir and peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control group (PR48, peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: T12PR48 group
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Lead-in T12PR48 group
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control group (PR48)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Telaprevir groups
Number of subjects: 663
Study: 19388860

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with cherry-flavored scent in oxygen (4 L/min)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 284
Study: 17531627

Group type: EXPERIMENTAL
Intervention: Endosonographers
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cytotechnologist
Number of subjects: 117
Study: 15156937

Group type: EXPERIMENTAL
Intervention: Patient educational program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 11801811

Group type: EXPERIMENTAL
Intervention: Oral piracetam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9721974

Group type: EXPERIMENTAL
Intervention: AT III supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional intensive care treatment
Number of subjects: 29